Advertisement

Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting

Published:October 12, 2021DOI:https://doi.org/10.1016/j.jvs.2021.09.045

      Abstract

      Background

      Clopidogrel resistance is associated with increased periprocedural neurologic events after carotid artery stenting (CAS). Ticagrelor offers an improved resistance profile; however, its bleeding risk has not been assessed with CAS. Therefore, we examined the efficacy and safety of perioperative dual antiplatelet therapy with aspirin/ticagrelor vs aspirin/clopidogrel in patients undergoing transfemoral carotid artery stenting (tfCAS) or transcarotid artery revascularization (TCAR).

      Methods

      We identified all patients who underwent tfCAS or TCAR in the Vascular Quality Initiative registry from January 2016 to March 2021. We stratified patients by procedure and assessed outcomes using 1:3 propensity score-matched cohorts of patients who received perioperative aspirin/ticagrelor vs aspirin/clopidogrel. The primary efficacy outcome was a composite endpoint of in-hospital stroke/death, and the primary safety outcome was access-related bleeding. As a secondary analysis, we assessed these outcomes after stratifying each cohort by intraoperative protamine use.

      Results

      Among 17,731 tfCAS patients, 593 (3.3%) received aspirin/ticagrelor and 11,404 (64%) received aspirin/clopidogrel. For the 2065 matched patients, no significant differences were found in the composite endpoint of stroke/death (aspirin/ticagrelor, 4.1%; vs aspirin/clopidogrel, 2.6%; relative risk [RR],1.5; 95% confidence interval [CI], 0.88-2.7) or in the individual endpoints of stroke (2.9% vs 1.8%; RR, 1.6; 95% CI, 0.87-3.0) or death (1.7% vs 1.1%; RR, 1.6; 95% CI, 0.71-3.5). However, aspirin/ticagrelor was associated with a higher risk of bleeding (5.8% vs 2.8%; RR, 2.0; 95% CI, 1.2-3.2). In a subgroup analysis of 297 tfCAS patients (14%) who received intraoperative protamine, no differences remained in stroke/death (1.5% vs 3.9%; RR, 0.38; 95% CI, 0.05-3.0), and there was no longer a difference in bleeding (3.0% vs 2.6%; RR, 1.1; 95% CI, 0.24-5.5). Among 17,946 TCAR patients, 453 (2.5%) received aspirin/ticagrelor and 13,696 (76%) received aspirin/clopidogrel. For the 1618 matched patients, no differences were found in stroke/death (0.7% vs 1.4%; RR, 0.53; 95% CI, 0.16-1.8), stroke (0.2% vs 1.2%; RR, 0.20; 95% CI, 0.03-1.5), death (0.5% vs 0.2%; RR, 3.0; 95% CI, 0.42-21), or bleeding (1.2% vs 1.6%; RR, 0.75; 95% CI, 0.28-2.0). For the 1429 TCAR patients (88%) who received protamine, no differences were found in stroke/death (0.8% vs 1.2%; RR, 0.68; 95% CI, 0.20-2.4) or bleeding (0.6% vs 1.4%; RR, 0.39; 95% CI, 0.09-1.7).

      Conclusions

      Compared with aspirin/clopidogrel, aspirin/ticagrelor was associated with a potentially lower risk of stroke/death and bleeding complications after CAS in cases in which protamine was used but a higher risk of these outcomes in the absence of protamine. Given our limited sample size, our analysis should be repeated when more patients are available for study. However, our findings suggest that aspirin/ticagrelor could be a reasonable alternative to aspirin/clopidogrel for both tfCAS and TCAR when protamine is used.

      Keywords

      To read this article in full you will need to make a payment
      SVS Member Login
      Society Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Huibers A.
        • Calvet D.
        • Kennedy F.
        • Czuriga-Kovacs K.R.
        • Featherstone R.L.
        • Moll F.L.
        • et al.
        Mechanism of procedural stroke following carotid endarterectomy or carotid artery stenting within the International Carotid Stenting Study (ICSS) randomised trial.
        Eur J Vasc Endovasc Surg. 2015; 50: 281-288
        • Ricotta J.J.
        • Aburahma A.
        • Ascher E.
        • Eskandari M.
        • Faries P.
        • Lal B.K.
        Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary.
        J Vasc Surg. 2011; 54: 832-836
        • Kuliczkowski W.
        • Witkowski A.
        • Polonski L.
        • Watala C.
        • Filipiak K.
        • Budaj A.
        • et al.
        Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
        Eur Heart J. 2009; 30: 426-435
        • Pandya D.J.
        • Fitzsimmons B.F.
        • Wolfe T.J.
        • Hussain S.I.
        • Lynch J.R.
        • Ortega-Gutierrez S.
        • et al.
        Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose.
        J Neuroimaging. 2010; 20: 64-69
        • Sorkin G.C.
        • Dumont T.M.
        • Wach M.M.
        • Eller J.L.
        • Mokin M.
        • Natarajan S.K.
        • et al.
        Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?.
        J Neurointerv Surg. 2014; 6: 373-378
        • Song T.-J.
        • Suh S.H.
        • Min P.-K.
        • Kim D.J.
        • Heo J.H.
        • Kim Y.D.
        • et al.
        The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting.
        Yonsei Med J. 2013; 54: 288-294
        • Husted S.
        • Emanuelsson H.
        • Heptinstall S.
        • Sandset P.M.
        • Wickens M.
        • Peters G.
        Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
        Eur Heart J. 2006; 27: 1038-1047
        • Storey R.F.
        • Husted S.
        • Harrington R.A.
        • Heptinstall S.
        • Wilcox R.G.
        • Peters G.
        • et al.
        Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
        J Am Coll Cardiol. 2007; 50: 1852-1856
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • et al.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Criteria Committee, New York Heart Association, Inc
        Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis.
        6th ed. Little, Brown, Co, Boston1964
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • Zhang Y.L.
        • Castro A.F.
        • Feldman H.I.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Ghamraoui A.K.
        • Ricotta II, J.J.
        Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization.
        J Vasc Surg. 2021; 73: 132-141
      1. National Average Drug Acquisition Cost 2021. U.S. Centers for Medicare & Medicaid Services, 2021 (Available at:)
        • Liang P.
        • Motaganahalli R.
        • Swerdlow N.J.
        • Dansey K.
        • Varkevisser R.R.B.
        • Li C.
        • et al.
        Protamine use in transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events.
        J Vasc Surg. 2021; 73: 142-150.e144
        • Aronow H.D.
        • Gray W.A.
        • Ramee S.R.
        • Mishkel G.J.
        • Schreiber T.J.
        • Wang H.
        Predictors of neurological events associated with carotid artery stenting in high-surgical-risk patients: insights from the Cordis Carotid Stent Collaborative.
        Circ Cardiovasc Interv. 2010; 3: 577-584
        • Khan M.
        • Qureshi A.I.
        Factors associated with increased rates of post-procedural stroke or death following carotid artery stent placement: a systematic review.
        J Vasc Interv Neurol. 2014; 7: 11-20
        • McDonald J.S.
        • Kallmes D.F.
        • Lanzino G.
        • Cloft H.J.
        Protamine does not increase risk of stroke in patients with elective carotid stenting.
        Stroke. 2013; 44: 2028-2030
        • Krakowiak A.
        • Kuleta J.
        • Plech I.
        • Zarebinski M.
        • Wojciechowska M.
        • Wretowski D.
        • et al.
        Ticagrelor-related severe dyspnoea: mechanisms, characteristic features, differential diagnosis and treatment.
        Clin Med Insights Case Rep. 2020; 13 (1179547620956634)